FDA says heartburn drugs can interfere with Plavix
WASHINGTON — Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.
The Food and Drug Administration said the stomach-soothing drugs Prilosec and Nexium cut in half the blood-thinning effect of Plavix, known generically as clopidogrel.
Regulators said the key ingredient in the heartburn medications blocks an enzyme the body needs to break down Plavix, muting the drug’s full effect. Procter & Gamble’s Prilosec OTC is available over-the-counter, while AstraZeneca’s Nexium is only available with a prescription.
“Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine,” the agency said in a statement.
Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion last year, it’s the world’s second-best selling drug behind Pfizer’s cholesterol drug Lipitor.
Because Plavix can upset the stomach, it is often prescribed with stomach acid-blocking drugs.
The FDA says patients who need to reduce their acid should take drugs from the H-2 blocker family, which include Johnson & Johnson’s Mylanta and Boehringer Ingelheim’s Zantac. FDA scientists say there is no evidence those drugs interfere with Plavix’s anti-blood clotting action.
Nexium and Prilosec are part of a class of drugs known as proton pump inhibitors, but FDA regulators said they don’t have enough information to say whether other drugs in that class shouldn’t be used with Plavix.
“There’s not enough data to tell us how those drugs interact with,” the enzyme that activates Plavix, said Mary Ross Southworth, FDA’s deputy director for safety of cardiovascular products. “There are ongoing studies looking at those other drugs.”
The FDA said the warnings on Plavix have been strengthened based on a 150-patient study submitted by Sanofi over the summer.
But some consumer advocates said the agency’s action fell short, arguing that regulators should have placed the information in a “black box” warning label, the most serious available.
“This information still has not risen to as prominent a level of warning as it should have,” said Dr. Sidney Wolfe, director of health research at the consumer advocacy group Public Citizen.
Information about the drug interaction between Plavix and other medications is not new. Researchers at pharmacy benefit manager Medco Health Solutions reported last year that taking Plavix with Nexium significantly increased patients’ chances of being hospitalized for a heart attack, stroke or chest pain.
In May, Sanofi and Bristol-Myers updated Plavix’s labeling to advise against using it in combination with certain heartburn drugs.
A Sanofi spokeswoman said Tuesday that the company has bolstered that language labeling.
“We’ve strengthened the label to say that these drugs should be avoided altogether, not just discouraged,” said Noelle Boyd, Sanofi’s senior communications director.
WBB Securities analyst Steven Brozak said the news would put pressure on Paris-based Sanofi and New York-based Bristol-Myers to provide more safety data on their best-selling product.
“This is going to create a chain reaction as patients start calling their physicians, and they are forced to make a spot decision on limited information,” said Brozak. “That’s not gonna help either company’s bottom line.”
Related News
FDA warns that heartburn drug Prilosec can block benefits of blood thinner PlavixNovember 17th, 2009 more images
more images
FDA says Prilosec can block benefits of Plavix
WASHINGTON — Federal health officials said Tuesday a popular heartburn medication can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke. The Food and Drug Administration said the stomach-soothing drug Prilosec cuts the blood-thinning effect of Plavix by half.
FDA approves first non-hormone therapy for excessive menstrual bleedingNovember 13th, 2009 more images
more imagesFDA approves new drug for heavy menstrual bleedingWASHINGTON — Federal health officials have approved a new drug as the first non-hormonal treatment for heavy menstrual bleeding. The Food and Drug Administration says Lysteda tablets reduce bleeding by acting on a protein that helps blood clot.
Teva Pharmaceutical receives FDA approval for generic version of heartburn drug PrevacidNovember 10th, 2009 more images
more imagesTeva gets FDA approval for generic PrevacidNEW YORK — Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
AstraZeneca posts 22 percent rise in third quarter profits amid demand for swine flu vaccineOctober 29th, 2009 more images
more images
AstraZeneca 3Q earns up 22 percent
LONDON — Pharmaceutical company AstraZeneca PLC posted a 22 percent rise in third quarter net profit on Thursday, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States. The expectation of further profits expected from its Novel Influenza A vaccine for the H1N1 led AstraZeneca to lift its full-year earnings forecast.
How BP could go out of hand during winter breakOctober 25th, 2009 WASHINGTON - While winter holidays are just round the corner, there are chances that people with high blood pressure might risk their health by overindulging in the season, warns an expert. Dr. Shawna Nesbitt, hypertension specialist at UT Southwestern Medical Center, said that about one in four Americans has hypertension, a disease that elevates blood pressure and can lead to a host of serious problems including heart attacks and strokes.
Practicing yoga or tai chi daily improves overall healthOctober 24th, 2009 WASHINGTON - Practicing yoga or tai chi 20 minutes each morning can help reduce stress, improve strength, limberness, provide better immune function and lower blood pressure. The major benefit of yoga and tai chi is that they combine key elements of exercise - aerobic, strength training, core stability, flexibility and balance - into unified approaches.
Drugmaker Bristol-Myers posts higher 3Q sales, but lower profit due to $2B gain a year agoOctober 22nd, 2009 Bristol-Myers posts higher 3Q sales, lower profitTRENTON, N.J. — Drugmaker Bristol-Myers Squibb Co.
Bristol-Myers faces growing competition for key drugs as it reports 3Q resultsOctober 21st, 2009 Earnings Preview: Bristol-Myers 3Q earnings reportNEW YORK — Bristol-Myers Squibb Co., the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning.
Medco says it will run clinical trial to compare blood thinners Plavix and EffientOctober 19th, 2009 Medco plans to compare Plavix, Effient in studyNEW YORK — Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with the newer Effient.
Heartburn drugs safe for foetuses, says Israeli studyOctober 8th, 2009 WASHINGTON - A new study done by Israeli scientists has shown that heartburn drugs are safe for the foetus. The study, conducted by researchers at the Ben-Gurion University of the Negev, Israel, has been published in the Journal of Clinical Pharmacology.
Saliva-based genetic test helps doctors identify patients who would not respond to PlavixOctober 7th, 2009 Test detects patients who don't respond to PlavixWASHINGTON — "Just spit." With those simple instructions, health care providers in California are hoping to expand the use of genetic testing to make sure patients get the right medication. Scripps Health hospital system has begun using a saliva-based genetic test to detect whether patients will respond to Plavix, a widely used blood thinner that usually prevents clots.
FDA tells doctors reformulated blood thinner heparin will be safer, but less potentOctober 1st, 2009 FDA tells doctors new heparin formula less potentWASHINGTON — The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors. The FDA said Thursday new heparin vials scheduled to begin shipping next week will be 10 percent less potent than the original blood thinner.
Middle-aged smokers with high cholesterol, BP 'cut life short by 10yrs'September 18th, 2009 LONDON - Middle-aged smokers with high cholesterol and blood pressure face a ten-year cut in their lives, warns a new study. The warning follows an Oxford University study of 19,000 men over an average of 38 years.
As you age, muscles get hard to build, easy to loseSeptember 12th, 2009 LONDON - Why do people's arms and legs get thinner as they age?
According to a team from Nottingham University (N-U) Schools of Graduate Entry Medicine, it could be due to the body's failure to deliver nutrients and hormones to muscle because of poorer blood supply. The researchers have already shown that older people cannot make muscle as fast as the young.
Cancer safety fears of most common heartburn treatment rejectedSeptember 10th, 2009 WASHINGTON - The largest ever study on 'Proton pump inhibitors' (PPI)-the second most prescribed group of drugs for heartburn-has dismissed all fears about the cancer causing effects of the treatment. PPI are the most commonly used treatment for chronic acid reflux, or 'heartburn', a painful burning sensation in the chest, neck and throat which is experienced by almost a third of people in developed countries.
